Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
VUA On Other Exchanges
As of 2:18 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

deutsche biotech innovativ a (VUA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/16/14 - €15.00
52 Week Low
05/13/15 - €10.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

deutsche biotech innovativ a (VUA) Related Businessweek News

No Related Businessweek News Found

deutsche biotech innovativ a (VUA) Details

Deutsche Biotech Innovativ AG, formerly known as Venetus Beteiligungen AG, is a principal investment firm. It invests primarily in companies with a focus on business concepts and technologies. Venetus Beteiligungen AG is based in Berlin, Germany.

deutsche biotech innovativ a (VUA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

deutsche biotech innovativ a (VUA) Key Developments

Deutsche Biotech Innovativ AG Successful Further Development of Sepsis and Cancer Drugs

Deutsche Biotech Innovativ AG made great progress in its R&D activities in fiscal year 2014 and during the first months of 2015. The focus of its research was on innovative candidate drugs for the treatment of sepsis (severe systemic bacterial infection) and breast cancer prevention as well as cancer treatment. Within the last year and a half, the Hennigsdorf-based biotech company near Berlin was able to successfully expand its preclinical product pipeline by three drug candidates. Preclinical studies show promising results: DBI's lead product is a partial agonist for treating sepsis, a disease that annually affects 15 to 19 million people worldwide and is fatal for 30% of these patients. There are currently no approved medications for treating sepsis. Adrecizumab, a humanized monoclonal antibody, developed by DBI is intended to be used for the causal and safe treatment of sepsis patients. The drug stabilizes the bioactivity of the peptide hormone adrenomedullin, thereby preventing organ failure during septic shock. After achieving very successful results during preclinical studies, DBI is currently preparing the phase I study. In addition, DBI is researching drugs for breast cancer prevention and cancer treatment. Aprepitant and AB2302 are two promising drug candidates. Aprepitant, an NK-1 receptor antagonist, is said to trigger controlled apoptosis (programmed cell death) in the presence of abnormal cells in women with an increased risk of breast cancer. The AB2302 antibody blocks adrenomedullin and restricts tumor growth by preventing the development of blood vessels.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VUA:GR €12.00 EUR 0.00

VUA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VUA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VUA Industry Range
No financial data is available for VUA.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEUTSCHE BIOTECH INNOVATIV A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at